Total Payments
$332,783
2024 Payments
$51,907
Companies
36
Transactions
600
Medicare Patients
1,365
Medicare Billing
$121,752
Payment Breakdown by Category
Other$254,481 (76.5%)
Travel$46,949 (14.1%)
Consulting$20,270 (6.1%)
Food & Beverage$10,975 (3.3%)
Education$108.12 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $240,871 | 132 | 72.4% |
| Travel and Lodging | $46,949 | 101 | 14.1% |
| Consulting Fee | $20,270 | 7 | 6.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $13,610 | 5 | 4.1% |
| Food and Beverage | $10,975 | 346 | 3.3% |
| Education | $108.12 | 9 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $136,369 | 213 | $0 (2024) |
| Allergan, Inc. | $132,625 | 190 | $0 (2020) |
| ABBVIE INC. | $44,646 | 57 | $0 (2024) |
| Shionogi Inc | $16,702 | 18 | $0 (2024) |
| Amgen Inc. | $469.28 | 24 | $0 (2024) |
| Merck Sharp & Dohme LLC | $248.60 | 14 | $0 (2024) |
| Insmed, Inc. | $211.43 | 14 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $148.17 | 8 | $0 (2024) |
| Melinta Therapeutics, LLC | $144.24 | 10 | $0 (2022) |
| La Jolla Pharmaceutical Company | $131.43 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $51,907 | 82 | ABBVIE INC. ($19,389) |
| 2023 | $34,201 | 86 | AbbVie Inc. ($16,083) |
| 2022 | $35,565 | 80 | Gilead Sciences, Inc. ($31,529) |
| 2021 | $23,686 | 48 | Gilead Sciences, Inc. ($17,856) |
| 2020 | $26,460 | 44 | Allergan, Inc. ($16,684) |
| 2019 | $66,915 | 122 | Allergan Inc. ($47,598) |
| 2018 | $56,126 | 86 | Allergan Inc. ($39,947) |
| 2017 | $37,923 | 52 | Allergan Inc. ($28,395) |
All Payment Transactions
600 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.80 | General |
| 12/09/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $43.55 | General |
| Category: HCV | ||||||
| 12/09/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $8.94 | General |
| Category: VIROLOGY | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.84 | General |
| 11/12/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,900.00 | General |
| Category: HCV | ||||||
| 11/11/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $27.06 | General |
| Category: HCV | ||||||
| 11/06/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $60.14 | General |
| Category: LIVER DISEASE | ||||||
| 11/05/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: Endocrinology | ||||||
| 10/22/2024 | Shionogi Inc | Fetroja (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,030.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/17/2024 | ABBVIE INC. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: VIROLOGY | ||||||
| 10/14/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/14/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: Diabetes Care | ||||||
| 10/07/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $5.12 | General |
| Category: VIROLOGY | ||||||
| 09/23/2024 | ABBVIE INC. | MAVYRET (Drug) | Travel and Lodging | In-kind items and services | $1,940.32 | General |
| Category: VIROLOGY | ||||||
| 09/23/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $161.25 | General |
| Category: VIROLOGY | ||||||
| 09/18/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,900.00 | General |
| Category: HCV | ||||||
| 09/16/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $32.55 | General |
| Category: HCV | ||||||
| 09/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.78 | General |
| 09/10/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/16/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: Diabetes | ||||||
| 08/14/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.46 | General |
| 08/13/2024 | ABBVIE INC. | DALVANCE (Drug) | Travel and Lodging | In-kind items and services | $1,528.74 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/13/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/08/2024 | Gilead Sciences, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| 07/24/2024 | ABBVIE INC. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| Category: VIROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 434 | 655 | $102,677 | $41,931 |
| 2022 | 8 | 328 | 451 | $69,058 | $28,887 |
| 2021 | 7 | 259 | 334 | $47,671 | $21,555 |
| 2020 | 9 | 344 | 441 | $68,516 | $29,379 |
Total Patients
1,365
Total Services
1,881
Medicare Billing
$121,752
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 130 | 153 | $40,086 | $15,273 | 38.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 88 | 191 | $25,785 | $11,533 | 44.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 53 | 83 | $12,782 | $5,275 | 41.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 54 | 68 | $7,238 | $3,309 | 45.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 34 | 74 | $5,846 | $2,807 | 48.0% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 23 | 24 | $4,896 | $1,430 | 29.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 21 | 21 | $3,297 | $1,210 | 36.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 31 | 41 | $2,747 | $1,094 | 39.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 69 | 124 | $16,492 | $6,736 | 40.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 60 | 97 | $15,028 | $6,593 | 43.9% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 74 | 84 | $16,280 | $6,316 | 38.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 50 | 66 | $6,982 | $3,245 | 46.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 29 | 30 | $7,140 | $3,103 | 43.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $2,928 | $1,254 | 42.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 16 | 16 | $2,512 | $985.53 | 39.2% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 18 | 22 | $1,696 | $654.44 | 38.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 44 | 59 | $9,086 | $4,478 | 49.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 54 | 86 | $9,030 | $4,378 | 48.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 37 | 40 | $9,320 | $4,163 | 44.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 45 | 67 | $8,509 | $3,704 | 43.5% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 35 | 35 | $6,195 | $2,562 | 41.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 25 | 25 | $3,925 | $1,620 | 41.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 19 | 22 | $1,606 | $650.98 | 40.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 74 | 81 | $18,873 | $8,686 | 46.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 93 | 165 | $16,540 | $5,667 | 34.3% |
About Dr. Fadi Al Akhrass, M.D
Dr. Fadi Al Akhrass, M.D is a Infectious Disease healthcare provider based in Pikeville, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/29/2010. The National Provider Identifier (NPI) number assigned to this provider is 1245557222.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Fadi Al Akhrass, M.D has received a total of $332,783 in payments from pharmaceutical and medical device companies, with $51,907 received in 2024. These payments were reported across 600 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($240,871).
As a Medicare-enrolled provider, Al Akhrass has provided services to 1,365 Medicare beneficiaries, totaling 1,881 services with total Medicare billing of $121,752. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Pikeville, KY
- Active Since 04/29/2010
- Last Updated 07/08/2022
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1245557222
Products in Payments
- Epclusa (Drug) $87,126
- DALVANCE (Drug) $81,184
- AVYCAZ (Drug) $70,517
- TEFLARO (Drug) $17,865
- Fetroja (Drug) $12,538
- MAVYRET (Drug) $7,678
- Veklury (Drug) $6,356
- Vosevi (Drug) $5,267
- Arikayce (Drug) $211.43
- DIFICID (Drug) $150.92
- Vabomere (Drug) $118.14
- JARDIANCE (Drug) $111.80
- XERAVA (Drug) $111.35
- FREESTYLE LIBRE 3 (Device) $109.79
- TAVNEOS (Drug) $106.84
- WATCHMAN Access System (Device) $97.83
- Aimovig (Biological) $92.55
- OFEV (Drug) $91.47
- BEXSERO (Biological) $85.90
- Prolia (Biological) $85.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.